Summary:
- The Li Ka Shing Foundation and Temasek Trust have jointly committed S$12 million to acquire systems and advance the clinical trial of an innovative cancer therapy called histotripsy in Singapore.
- Histotripsy is a non-invasive, targeted cancer treatment that uses focused ultrasound to selectively destroy tumor cells without damaging surrounding healthy tissue.
- This investment will help accelerate the development and testing of this promising new cancer treatment, which could potentially offer a less invasive and more effective alternative to traditional cancer therapies.